Description

Tirzepatide represents an innovative synthetic peptide designed as a dual agonist for both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, incorporating advanced peptide engineering to achieve balanced activity at both receptor systems. The compound consists of a 39-amino acid linear peptide chain with structural similarities to both GIP and GLP-1, belonging to the secretin family of gut hormones. The compound features a C20 fatty diacid modification that significantly enhances stability and extends half-life through albumin binding. Tirzepatide functions through simultaneous activation of both GIP and GLP-1 receptors, leading to complementary signaling cascades that influence glucose homeostasis, insulin secretion, and metabolic regulation. Research applications include investigation of dual incretin signaling, glucose homeostasis mechanisms, and metabolic regulation pathways. For research use only.